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RANDOMIZED, PROSPECTIVE TRIAL OF CYCLOSPORINE 
MONOTHERAPY VERSUS AZATHIOPRINE-PREDNISONE FROM 
THREE MONTHS AFTER RENAL TRANSPLANTATION1
L u k as  B. H i lb r a n d s ,2 A n d r ie s  J .  H o itsm a, a n d  R o b e r t  A.P. K oene
D ep a r tm en t o f  M edicine, D iv is ion  o f  Nephrology, University H osp ita l N ijm egen, N L-6500  H B  N ijm egen, The Netherlands
Cyclosporine (CsA) and prednisone (Pred) are the 
most w idely used drugs for immunosuppression after 
renal transplantation, but both drugs have marked 
side effects. Either replacem ent of CsA by azathio- 
prine (Aza) or withdrawal of prednisone (Pred) result­
ing in  CsA monotherapy can be employed to circum­
vent the adverse effects in the long run. Both 
treatm ent regim ens were compared in this prospec­
tive randomized trial in  patients who were treated 
w ith CsA and Pred during the first 3 months after 
renal transplantation (CsA: n=64, Aza-Pred: n==63, me­
dian duration of follow-up: 3.9 years). Estimated graft 
survival rates at 5 years after transplantation (in pa­
tients w ith a functioning graft at 3 months) were 78% 
in the CsA group and 87% in the Aza-Pred group. The 
incidence of a rejection w ithin 3 m onths after start of 
steroid withdrawal or conversion from CsA to Aza was 
30% and 25%, respectively (NS). At 2 years after trans­
plantation, serum creatinine levels were lower in the 
Aza-Pred group (126±35 fxmol/L) than in the CsA 
group (180±78 ¿imol/L; P < 0.001). There were no differ­
ences in blood pressure or incidence of infections be­
tween the treatm ent groups. Treatment-related costs 
were measured during the first year after transplan­
tation and were lower in the Aza-Pred group (DFL 
40,882±18,895 vs. DFL 53,484+44,828; 1 DFL [Dutch 
guilder] is about US $0.60; P<0.05). In conclusion, CsA 
monotherapy and Aza-Pred treatm ent from 3 months 
after renal transplantation are comparably effective 
immunosuppressive treatm ent regimens, although 
Aza-Pred therapy results in better graft function. 
Withdrawal of steroids and replacem ent of CsA by Aza 
both carry a substantial risk of rejection. The previ­
ously dem onstrated cost effectiveness of CsA-contain- 
ing therapies seems to be lim ited to the first phase 
after transplantation. Conversion to Aza-Pred at 3 
months after transplantation reduces costs.
The combination of cyclosporine (CsA*) and prednisone 
(Pred), frequently supplemented by azathioprine (Aza), is 
widely used as a standard immunosuppressive drug regimen 
after renal transplantation. Although data regarding graft 
survival with the use of these drugs are quite satisfactory, 
concern remains about their side effects, especially when 
they are used chronically. Pred is feared for its effects on 
bone metabolism and skin, its potential to induce hypergly­
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cemia, hyperlipidemia, and cataract, and its contribution to 
hypertension (1 , 2). The nephrotoxic properties of CsA are 
well known and long-term use of this drug has been associ­
ated with irreversible loss of graft function due to vascular 
obliteration and interstitial fibrosis (3), although recent data 
on this issue are less worrisome (4 , 5). In addition, CsA 
importantly contributes to posttransplant hypertension (6 ) 
and has also been implicated in the pathogenesis of hyper­
cholesterolemia in these patients (2). To reduce the incidence 
of these long-term adverse effects in patients treated with 
CsA and Pred, two strategies may be followed. One is to 
withdraw the steroids, leading to CsA monotherapy. Alter­
natively, CsA can be replaced by Aza, a drug with a less 
impressive side effect profile, with continuation of Pred. Con­
version from CsA to Aza at 3 months after renal transplan­
tation has been our standard protocol during recent years. In 
different studies, both CsA monotherapy (7-9) and conver­
sion from CsA to Aza {10-13) have been demonstrated to yield 
adequate results in terms of graft survival and graft function. 
In 1989, we initiated a randomized, prospective trial to com­
pare these two treatment regimens with respect to efficacy, 
side effects, and costs. All patients were on CsA and Pred 
until 3 months after transplantation, when they were ran­
domized to CsA monotherapy or Aza-Pred. With a duration of 
follow-up of at least 2  years in all patients, this article de­
scribes the results with emphasis on rejection incidence, 
graft function, and costs. Detailed data on the effects of both 
therapies on quality of life (14) and lipid metabolism (15) 
during the first year after transplantation are published 
separately.
PATIENTS AND METHODS
P atien t popu la tion  a n d  random iza tion  procedure . From June 
1989 to June 1992, all 236 adult patients who underwent a first or 
second cadaveric renal transplantation at our institution were can­
didates for this study. Patients were excluded when they fulfilled one 
or more of the following exclusion criteria: age above 65 years 
(n-10), history of psychiatric disease or alcohol abuse (n=14), his­
tory of malignancy (n=7), signs of active hepatitis or carriage of 
hepatitis B surface antigen (n~7), hemolytic uremic syndrome as 
original kidney disease (n=6), use of antiepileptic drugs (n=5), and 
allergy to Aza (n=2). Quality of life measurements necessitated the 
exclusion of patients with poor knowledge of Dutch language (n=16). 
Finally, five patients refused to participate, bringing the number of 
patients who were eligible for the study to 185.
Patients received CsA and Pred during the first 3 months after 
transplantation. Afterward, they were allocated to CsA monotherapy 
or to the combination of Aza and Pred. Treatment allocation was 
carried out by the minimization method (16) with frequency match­
ing for the following factors: sex and age (<40 and >40 years) of the 
recipient, diabetes mellitus (yes/no), type of previous renal replace-
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ment therapy (hemodialysis or continuous ambulatory peritoneal 
dialysis), previous transplantation (yes/no), number of rejection ep­
isodes (0, 1 , or ^ 2), treatment with antithymocyte globulin during 
the first 3 months (yes/no), temporary interruption of CsA therapy 
(<10  or ^10 days), graft function (creatinine clearance <50, 50-75,
or > 75  ml/min), proteinuria (<0.1, 0.1-1.0, or >1.0 g/L), number of 
antihypertensive drugs (0, 1 , 2, or S:3), and age of the donor (slO, 
11-50, or >51 years). At 3 months after transplantation, 58 of the 
185 eligible patients could not be allocated to one of either treatment 
arm. Main causes were a relatively high incidence of patient death 
(n = 8) and graft loss (n=30), resulting in a graft survival rate of 79% 
at 3 months after transplantation. Other reasons to withdraw pa­
tients from  randomization were: loss of patient to follow-up (n=l), 
contraindication for CsA by clinical judgment (usually because of 
signs of CsA nephrotoxicity; n -17 ), use of Aza contraindicated be­
cause of bone marrow depression (n= l), and use of Pred contraindi­
cated because of severe osteoporosis (n= l). The remaining 127 pa­
tients made up our study population.
Postulating a 2-year graft survival (starting with 100% at 3 
months after transplantation) of 80% with our standard therapy, 80 
patients on each treatment were required to provide 80% power of 
detecting a difference in graft survival of 15%. Lower than expected 
patient accrual and a high incidence of graft loss before randomiza­
tion resulted in a somewhat fewer number of patients in each group 
after the 3-year accrual period.
The most frequent causes of renal insufficiency in the study pa­
tients were chronic pyelonephritis (n = 20), autosomal dominant poly­
cystic kidney disease (n=13), and IgA nephropathy (n=9). Two pa­
tients (both in the CsA group) had diabetic nephropathy and in 22 
patients the cause of renal failure was unknown.
A prognostic index, a score including information on both the 
donor and recipient that was developed to predict graft survival, was 
calculated according to Thorogood et al, (17).
S t u d y  p ro to c o l , The surgical procedure included infusion of man- 
nitol and a m oderate hydration protocol, as described previously (18). 
A f t e r  surgery, CsA was given intravenously (3 mg/kg/day) for the 
first 3 days, followed by 12 mg/kg/day in two divided oral doses 
during the first month. This was gradually reduced to 4 mg/kg/day at
3 months after transplantation, with the dosage adjusted to main­
tain CsA trough blood levels between 200 and 400 ng/ml (monoclonal 
antibody assay). In case of signs of severe CsA nephrotoxicity, tem­
porary replacem ent of CsA by Aza (3 mg/kg) was allowed. Pred­
nisolone was given at a dose of 100 mg/day i.v. during the first 2 days, 
followed by an oral Pred dosage of 25 mg/day during the remainder 
of th e first m onth and 20 mg/day during the second and third month 
after transplantation. In patients who were randomized to receive 
C sA  monotherapy, CsA was continued in the same dosage with 
adjustm ents to reach trough blood levels between 100 and 200 ng/ml 
(monoclonal antibody assay). The daily Pred dosage was reduced by 
5 m g  every 2 weeks, which resulted in CsA monotherapy after 6 
w eek s. In patients allocated to Aza-Pred therapy, CsA was replaced 
w ith ou t overlap by Aza in a dosage of 3 mg/kg. Their Pred dosage was 
tem porarily increased from 20 to 25 mg/day and reduced by 5 mg 
every  2 w eeks until a maintenance dose of 10 mg/day was reached. In 
th e  CsA group, Pred was restarted if more than one acute rejection 
or chronic vascular rejection occurred after randomization. The same 
conditions led to replacement of Aza by CsA in the Aza-Pred group. 
In  case of severe and persistent side effects, attributable to one of the 
drugs, patients were put on the alternative treatment regimen.
T he diagnosis of acute rejection was made on clinical grounds and 
histologically confirmed in 81% of cases. During the first 3 months 
a fter  transplantation, acute rejection episodes were treated with 
m ethylprednisolone (1 g/day i.v. on 3 consecutive days) or antithy­
m ocyte globulin (ATG, RIVM Bilthoven, The Netherlands; 200 mg/ 
d ay  i.v. on alternate days for 10 days). An oral course of high-dose 
P red  (initial dosage 200 mg/day tapered to 25 mg/day in 12 days) was 
g iven  after failure of one or both of these treatments. From 3 months 
after transplantation (i.e., after randomization), acute rejection epi­
sodes were treated primarily with ATG in all cases. High-dose Pred 
courses were given in case of failure of ATG, bone marrow suppres­
sion, or previous treatment with ATG for rejection. Occasionally, 
acute rejection episodes were treated with monoclonal anti-CD3 
antibodies.
Hypertension, defined as diastolic blood pressure above 95 mmHg 
on three consecutive occasions, was initially treated in a standard 
way using a j3-blocker (atenolol), followed by the addition of a calci- 
um-antagonist (nifedipine) and a diuretic (chlorthalidone) when nec­
essary. Beyond the first year after transplantation, when most pa­
tients were seen in different community hospitals, antihypertensive 
therapy reflected local practice.
Body weight and blood pressure as well as results from routine 
clinical chemistry were recorded at regular intervals as part of the 
usual posttransplant patient evaluation. A diagnosis of urinary tract 
infection was made when a positive urine culture prompted antibi­
otic therapy. Cytomegalovirus infection was defined by a 4-fold rise 
in IgG antibody titer. The diagnosis of other infections was based on 
clinical judgment. Creatinine clearance was estimated with the for­
mula given by Cockcroft and Gault (19). Proteinuria was defined as 
urinary protein concentration of 0.2 g/L  or more (24-hr urinary 
protein excretion was not measured routinely). Whole blood CsA 
levelB were measured with a fluorescence polarization immunoassay 
(Abbott Laboratories, North Chicago, IL), initially using polyclonal 
antibodies directed against the parent molecule of CsA and some of 
its metabolites. The majority of blood levels were measured with a 
modified kit, using monoclonal antibodies against the CsA parent 
molecule without cross-reactivity, A conversion factor of 0.5 was used 
to adjust the initial values to those currently measured.
The study was approved by the hospital ethics committee and all 
patients gave written informed consent.
Cost a n a ly s is . The health care costs directly related to either 
treatment regimen were calculated for the first year after transplan­
tation. Costs of kidney acquisition and indirect costs to society, e.g., 
costs related to disablement, were not considered. Two patients who 
died, two patients with graft loss, and one patient in whom insuffi­
cient data were available were excluded from this analysis (death 
and graft loss were evenly distributed among both groups). The 
medical records were used as a data source for number of admission 
days, number of visits to the outpatient clinic, and amounts of all 
drugs that were-used during hospital stays (except drugs used in the 
operating room) as well as on an outpatient basis. Similarly, the 
number of blood products administered and the number of CsA blood 
level measurements were counted. Our hospital financial adminis­
tration service provided data on activities regarding the following 
items: clinical laboratory, operating room and anesthesia, diagnostic 
radiology, nuclear medicine, endoscopy, pathology, and physiother­
apy. Prices current during 1993 or 1994, and expressed in Dutch 
guilders (1 DFL is about US $0.60) were used to calculate costs. The 
direct costs of hospital days and visits to the outpatient clinic were 
estimated on the basis of personnel costs and material expenses 
(excluding medication and blood products) and amounted to about 
DFL 300 and DFL 75, respectively. For the intensive care unit, costs 
were estimated at DFL 2000 per day. The costs of other services were 
assessed in an analogous way, and when reliable estimations were 
not attainable (as for laboratory services), charges were used as a 
proxy for costs.
S ta i is t ic a l  analysis . The results were analyzed on an intention- 
to-treat basis. Calculations were performed with the SAS system  
(SAS Institute Inc., Cary, NC). Data are given as means with SD  
unless stated otherwise. Unpaired and paired comparisons of numer­
ical data were performed with Wilcoxon’s rank sum and signed ranks 
tests. Proportions were compared with chi-square analysis using  
continuity correction or with McNemar’s test when appropriate. 
Probabilities of survival were calculated using the Kaplan-Meier 
product lim it method and for comparison of survival curves the log  
rank test w as used, A P-value smaller than 0.05 was considered 
statistically significant.
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RESULTS
The characteristics of patients and their kidney donors are 
given in Table 1. Except for a better degree of HLA-B match­
ing in the Aza-Pred group, there were no significant differ­
ences between the treatm ent groups. In addition, the 58 
patients who initially were eligible for the study but could not 
be randomized at 3 months after transplantation did not 
differ with regard to these baseline characteristics, At the 
time of randomization, there were no differences between 
groups in regard to clinical data (Table 1). The median du­
ration of follow-up in patients with still-functioning grafts 
was 3.9 years (range: 2.7-5 . 6  years).
Course o f treatment. Since the originally assigned treat­
ment was changed for various reasons in a considerable 
number of patients, an overview of the course of treatment in 
all randomized patients is given in Table 2. In some patients, 
the immunosuppressive treatment regimen had to be 
changed for a second or third time. Despite the numerous 
changes, all data were analyzed according to the intention- 
to-treat principle. In patients who died or in whom graft 
failure occurred (n—2 1 ), therapy had been changed previ­
ously in seven cases. Persistent symptoms of a steroid with­
drawal syndrome (fatigue, arthralgia) necessitated tempo­
rary reinstitution of steroids in three CsA-treated patients, 
but eventually these patients received CsA monotherapy. In 
the CsA group, the CsA dose gradually decreased from 
4.0 ±1.0 mg/kg/day at the end of the first year to 2.9±0.9 
mg/kg/day at the end of the fifth year after transplantation. 
Only CsA trough levels that were measured during the first
9 months after allocation to CsA monotherapy were ana­
lyzed, since beyond this period most of the patients were seen 
in various community hospitals, which used different analyt­
ical techniques to determine CsA levels. The frequency of 
levels below the target range varied from 2% at 5 months 
after transplantation to 7% at 4 months after transplanta­
tion.
Patient and graft survival. Estimated 5-year patient sur­
vival rates (in survivors at 3 months) were 92% and 95% in 
the CsA and Aza-Pred group, respectively. The death of six 
patients in the CsA group was caused by pneumonia (n=3, 
caused by Pneumocystis carinii in one case), myocardial in­
farction (n=l), rupture of abdominal aortic aneurysm (n=l), 
and uterine cervix carcinoma (n=l). In the Aza-Pred group, 
three patients died. Causes of death were myocardial infarc­
tion, brain hemorrhage, and malignant lymphoma of the 
lungs. Kaplan-Meier plots of probability of graft survival 
(death with a functioning graft was considered as graft fail­
ure) are shown in Figure 1 , Probabilities of survival with a 
functioning graft at 5 years after transplantation (again 
starting with 100% at 3 months after transplantation) were 
estimated to be 78% in the CsA group and 87% in the Aza- 
Pred group (NS). In one patient, a recurrence of focal glomer­
ular sclerosis led to return to dialysis. All other graft failures 
in surviving patients (eight in the CsA group and three in the 
Aza-Pred group) were due to rejection.
Rejection episodes. From the time of randomization until 
the end of follow-up, a total number of 6 8  rejections were 
diagnosed in 46 patients. In the CsA group, 43 rejections
T ab le  1 . Patient and donor characteristics in 127 study patients who participated in a randomized trial comparing CsA monotherapy
with an Aza-Pred combination
CsA Aza-Pred
(n-64) (n=63)
Data at time of transplantation *
Sex (M/F) 40/24 41/22
Age (yr) 43 ±13 42 ±14
Time on dialysis (mo) 30 ±22 27 ±17
No. of graft (first/second) 52/12 53/10
Cold ischemia time (hr) 30±7 30±7
Age of donor (yr) 42 ±16 39 ±17
Highest % panel reactive antibodies (^5%/5-85%/>85%) 25/37/1° 30/30/2“
No. of mismatches on
HLA-A (0 /a l) 23/41 33/30
HLA-B (0/2:1) 19/45 38/25*
HLA-DR (0/2*1) 46/18 53/10
Prognostic index scorec
First transplants 0.87±0.37 0.76±0.36
Second transplants 0.78±0.28 0.48±0.36
Clinical data at time of randomization (3 mo after transplantation)
Requirement for dialysis after transplantation (%) 22 (34) 15 (24)
Temporary interruption of CsA treatment (%) 14 (22) 12 (19)
One or more acute rejections during first 3 mo (%) 17 (27) 16 (26)
Serum creatinine (/xmol/L) 158±60 151+39
Estimated creatinine clearance (ml/min) 55±19 56+19
Proteinuria ^ 0.2 g/L (%) 10 (16) 10(16)
Systolic blood pressure (mmHg) 154±26 153±21
Diastolic blood pressure (mmHg) 92±11 92±8
Use of antihypertensive drug(s) (%) 45 (70) 47 (75)
“ No data were available for one patient in each group. 
b P <0.001  for difference between the groups.
c A higher prognostic index score indicates worse graft prognosis of a first or second graft. The scores for first and second grafts are 
calculated using different formulas and cannot be compared.
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T a b le  2. Course of treatment in 127 patients who were allocated to treatment with CsA monotherapy or Aza-Pred
1 2
Year after transplantation
3 4 5
CsA
Patients with sufficient length of follow-up“ 64 62 52 26 8
Patient death/graft failure6,c 1/1 2/1 2/5 —/I ---/---
Reasons to deviate from originally assigned therapy4* 
-fPred 
^ 2  Acute rejections 4
Chronic rejection 4 3 2 ---------- ----------
Other reasons 4 1 1 ---------- ----------
CsA —» Aza-Pred 
CsA nephrotoxicity 11 2 _ _
Other reasons 1 1 ---------- ---------- ----------
+ Aza-Pred 
Chronic rejection and CsA nephrotoxicity 1 1
Immunosuppressive therapy at end of each year 
Continuously on CsA monotherapy 37 28 21 14 4
CsA monotherapy after interruption by other therapy ---------- 1 1 1 ----------
Pred ---------- 1 ---------- ---------- ----------
CsA-Pred 13 13 13 6 3
Aza-Pred 11 10 9 3 1
CsA-Aza-Pred 1 6 1 1 ----------
Aza-Pred
Patients with sufficient length of follow-up° 63 61 50 28 6
Patient death/graft failure6 1/1 2/1 ----------f --------- — 12 — /—
Reasons to deviate from originally assigned therapy"* 
Aza-Pred - » CsA 
^2  acute rejections 2 1
Bone marrow suppression 8 4 ---------- ---------- —
Elevated liver enzymes 4 ---------- ---------- ---------- —
Other reasons ---------- 1 1 ---------- —
Immunosuppressive therapy at end of each year 
Continously on Aza-Pred 47 40 35 19 6
Aza-Pred after interruption by other therapy 2 3 3 2 ----------
CsA 7 6 6 3
CsA-Pred 5 9 6 2 ----------
a Patients who died or lost graft function during preceding years were excluded,
b The number of patients with a functioning graft at the end of each year equals the number of patients with sufficient length of follow-up 
minus the number of patients who died or returned to dialysis during that year. 
c One patient died during the sixth year of follow-up.
d Following the deviation of the originally assigned therapy, treatment was changed for a second or third time in some patients (e.g., 
conversion from CsA to Aza-Pred was sometimes followed by reconversion to CsA-Pred).
occurred in 27 patients (42% incidence of at least one rejec­
tion), whereas in the Aza-Pred group 25 rejections were 
found in 19 patients (30%; NS for difference with CsA). Thir­
ty-five (76%) patients of those with at least one rejection after 
randomization had no rejection during the first 3 months 
after transplantation. In the majority of cases, rejections 
became manifest within 3 months after start of steroid with­
drawal or conversion from CsA to Aza randomization (CsA: 
19/27, Aza-Pred: 16/19). For rejections occurring between 
randomization and the end of the first year after transplan­
tation, the interval between randomization and rejection was 
significantly shorter in the Aza-Pred group (CsA [n=26]: 
12± 8  weeks, Aza-Pred [n=18]: 6±7 weeks; P<0.01), Thus, 
the incidence of acute rejection within 4 weeks after change 
of therapy was 3% in the CsA group as compared with 19% in 
the Aza-Pred group (P=0 .0 1 ). A histologic diagnosis of 
chronic vascular rejection was made in 17 patients in the CsA 
group and in 1 2  cases in the Aza-Pred group (NS). Time from 
transplantation until the diagnosis of chronic rejection was 
comparable in both groups (median [range]: CsA, 9 months
[4-33]; Aza-Pred, 7 months [4-42]; NS). In all but three 
CsA-treated and all but four Aza-Pred-treated patients, 
chronic rejection was preceded by one or more acute rejection 
episodes.
Patients in whom one or more rejection episodes occurred 
after allocation to CsA or Aza-Pred treatm ent did not differ 
from those without rejections with respect to various clinical 
and immunological risk factors, prognostic index score, or 
proportion of patients with rejections in the first 3 months 
after transplantation. Likewise, the 11 patients in whom 
rejection ultimately resulted in graft failure were not char­
acterized by extreme levels of HLA mismatches, percentage 
panel reactive antibodies, or prognostic index score. Remark­
ably, however, nine of these patients had been free of any 
rejection episode a t the time of conversion or at the start of 
steroid taper, and in eight of these nine patients, a rejection 
episode occurred between 4 and 20 weeks after the changes 
in therapy. Expressed in another way, in patients who had a 
first rejection episode between 4 and 20 weeks after steroid 
withdrawal or conversion from CsA to Aza at 3 months after
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Graft survival
Time a fte r  tran sp lan ta tio n  (years)
Figure 1. Kaplan-Meier graft survival curves of the two treatment 
groups.
transplantation (n=31), the risk of subsequent graft failure 
due to rejection was 26%.
When event-free survival was defined as survival with a 
functioning graft without diagnosis of acute or chronic rejec­
tion, the probability of this survival at 5 years after trans­
plantation was estimated to be 48% and 65% in the CsA and 
Aza-Pred groups, respectively (NS).
Graft function and blood pressure. As expected, conver­
sion from CsA to Aza was followed by a sustained improve­
ment in graft function (Table 3). During the first 3 months 
after this conversion, the increase in estimated creatinine 
clearance was 19 ±20% (P<0.001). After withdrawal of ste­
roids in the CsA monotherapy group, a slight increase in 
serum creatinine was observed. This could not be attributed 
to the occurrence of rejection, since a rise in creatinine 
(7.5±13.9% between 3 and 6  months after transplantation, 
P<0.01) was still present after patients with a rejection or 
overt signs of CsA nephrotoxicity had been excluded. Re­
stricting the comparison between the groups to rejection-free 
patients who were kept on their originally assigned therapy
resulted in 1 -year serum creatinine levels of 148±40 fxmol/L 
and 122±30 jumol/1 in the CsA and Aza-Pred groups, respec­
tively (P<0.05). Except for a transiently lower frequency of 
proteinuria at 6  months after transplantation in the CsA 
group, there were no differences in the incidence or degree of 
proteinuria (latter data not shown). Similar reductions in 
systolic as well as diastolic blood pressure were observed 
after withdrawal of steroids or conversion from CsA to Aza 
(change in systolic blood pressure between 3 and 6  months 
after transplantation: —6±13% vs. -6±14% [NS], change in 
diastolic blood pressure: —5±17 vs. ~7±12% [NS]). Although 
diastolic blood pressure tended to be higher in the CsA group, 
the difference only reached statistical significance at 4 years 
after transplantation. Antihypertensive therapy was consid­
ered necessary in about two thirds of all patients during the 
first year after transplantation and the requirement for blood 
pressure reduction did not decline during subsequent years. 
There was no difference in the need for antihypertensive 
treatment between both groups.
Infections, During the universally completed follow-up pe­
riod of 2  years after transplantation, there were no differ­
ences between the groups with regard to the number of 
patients with urinary tract infections, respiratory tract in­
fections, cytomegalovirus infections, or the combined inci­
dence of all other infections.
Cost analysis. Direct treatment-related costs during the 
first year after transplantation were higher in the CsA group 
(P<CLG5, Table 4 and Fig. 2 ). The majority of data allowed 
separate analyses for the periods before and after random­
ization, As expected, there were no significant differences 
between the groups before randomization. After randomiza­
tion, the CsA group was characterized by significantly higher 
drug costs and costs of CsA level measurements. These dif­
ferences, as well as a tendency to higher costs of hospitaliza­
tion in the CsA group, mainly accounted for the difference in 
total whole-year costs. In the CsA group, whole-year costs of 
CsA comprised 6 8 % of all drug costs, as compared with 48% 
in the Aza-Pred group. When only the period after random­
ization was included in the calculations (months 4-12), these 
figures were 67% and 19% respectively. When costs of stan­
dard immunosuppressive therapy (CsA, Aza, and Pred) and 
of CsA level measurements were not considered, mean costs
Table 3. Graft function and blood pressure during follow-up in patients who were allocated to treatment with CsA monotherapy or Aza-
Pred from 3 months after renal transplantation“
Time after Tx
Serum creatinine (/xmol/L) Proteinuria 5:0.2 g/L {%)
Systolic blood pressure 
(mmHg)
Diastolic blood pressure 
(mmHg)
Use of 
antihypertensive 
drugs (%)
CaA Aza-Pred CsA Aza-Pred CsA Aza-Pred CsA Aza-Pred CsA Aza-Pred
3 Months 158±60 151±39 16 16 154±26 153±21 92±11 92±8 70 75
6 Months 162±46ò 134±34c,¿¿ 13 32e 142±20e 142±20c 86+ 10* 85±10c 74 64
9 Months 170±49c 133±34c,c¿ 16 22 145 ±20 146±22 88 ^ lo*- 8 7 ± l l fa 69 62
1 Year I76±69ò 131±37c'd 20 27 144±18/ 144±22/' 89±8 86 ± 8° 66 66
2 Years 180±78^ 126±35c,d 32 26 142 ±19° 144 ±206 87 ± Xlf 86±9C 81 74
3 Years 173±78 130±49CjC 29 28 146 ±17^ 142 ±236 87±11/' 84±13c 81 71
4 Years 169 ±64 134±536 35 19 146 ±19 149 ± n f 89±7 82±9c,e 73 78
° The numbers of patients with a duration of follow-up of more than 4 years were too small for meaningful comparisons.
b P<0.01 for differences with baseline values at 3 months after transplantation.
c jP<0,001 for differences with baseline values at 3 months after transplantation.
d P<0.001 for differences between the CsA and Aza-Pred groups.
e P<0.05 for differences between the CsA and Aza-Pred groups.
f P < 0.05 for differences with baseline values at three months after transplantation.
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Table 4. Direct treatment-related costs per patient during the first year after transplantation in patients who were allocated to
treatment with CsA monotherapy or Aza-Preda
CsA Aza-Pred
A, Hospitalization
Months 1-3 8,311+4,692 8,036±4,351
Months 4-12 10,5202:30,609 5,579 ±8,925
Entire year 18,831*31,444 13,615± 10,159
B. Drugs
Months 1-3 5,641 + 2,598 5,829 ±2,677
Months 4-12 9,064+4,713 4,280 + 4,062*
Entire year 14,706±5,361 10,109±4,680*
C, Visits to outpatient clinic
Months 1-3 816+189 852±185
Months 4-12 1,554+597 1,499 ±449
Entire year 2,370 + 625 2,351±502
D. CsA level measurements
Months 1-3 965±365 1,020±387
Months 4-12 1,009+459 173±3476
Entire year 1,975 + 675 l,194±495ò
E, Renal replacement therapy
Months 1-3 551+1,316 374±881
Months 4—12 109+788 35±273
Entire year 660 + 1,497 409±908
A + B Hh C H- D ■+■ E
Months 1-3 16,285+7,023 16,1U ±6,674
Months 4-12 22,257+33,727 11,566+11,878*
F, Laboratory services (excl. CsA levels) 9,453+7,352 8,516±3,207
G. Other diagnostic and therapeutic activities 4,944±3,882 4,335±4,425
H. Blood products 545+1,168 355±571
Total costs 53,484+44,828 40,882± 18,895e
° When available, separate data are given for months 1 to 3 (i.e., before randomization) and months 4 to 12, Costs are expressed in Dutch 
guilders. One Dutch guilder is about US $0.60, 
bP < 0.001 for differences between the groups. 
c P < 0.05 for differences between the groups.
Proportion of patients (%)
60
40 -
20
0
□  CsA
Aza-Pred
<  25,000 25,000-
50,000
50,000“ 2> 75,000
75,000
Total costs (DFL)
F igure 2. Proportion of patients in different categories of total 
treatment-related costs during the first year after transplantation.
per patient decreased to DFL 41,155 ±44,890 and DFL 
33,655 ±18,919 in the CsA and Aza-Pred groups, respectively 
(NS). Exclusion of five patients who were admitted to the 
intensive care unit (three patients from the CsA group and 
two from the Aza-Pred group) resulted in a reduction of the 
mean costs of hospitalization by more than 2 0 %. In the re­
maining patients, total costs did not significantly differ be­
tween the groups (CsA: DFL 44,311 ±17,159, Aza-Pred: DFL
39,624±17,873). Not surprisingly, in patients who experi­
enced one or more rejection episodes during the first year 
after transplantation costs were significantly higher than  in 
patients without any rejection (DFL 56,717±39,406 vs. DFL 
37,333±26,250; P < 0 .0 0 1 ). Occurrence of a rejection episode 
after the time of allocation to either treatm ent group resulted 
in an increase of total costs by DFL 21,557 per patient in the 
CsA group and by DFL 17,054 per patient in the Aza-Pred 
group.
DISCUSSION
This study demonstrates that CsA monotherapy and Aza- 
Pred treatment from 3 months after renal transplantation 
are comparably effective immunosuppressive treatment reg­
imens in terms of patient and graft survival. Keeping in mind 
that survival curves departed from 100% at 3 months after 
transplantation, the observed patient and graft survival 
rates agree with the pooled results of other centers using 
CsA-based immunosuppressive regimens (20, 21). However, 
the relatively small sample size of the current study may 
have obscured a difference in graft survival between the 
groups.
One of our major findings was the rather high incidence of 
acute rejections after both steroid withdrawal and conversion 
from CsA to Aza. In several studies the risk of having an 
acute rejection episode has been shown to decrease with time, 
and most patients free of rejection at 3 months after trans­
plantation remained so during the rest of the first posttrans­
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plantation, year (22, 23). In the current study, however, the 
number of patients with rejections between 3 and 12 months 
after transplantation exceeded the number of patients with 
rejections during the first 3 months in both treatment 
groups. Acute rejections tended to be more frequent in the 
CsA group but the difference did not reach statistical signif­
icance. The 19% incidence of acute rejections within the first 
month after conversion from CsA to Aza was relatively high 
as compared with our previous experience of only 6 % (24), We 
do not have a clear explanation for this discrepancy since the 
same treatment schedule, including temporary increase of 
the prednisone dosage following conversion, was used. With 
either an overlap between CsA and Aza treatment of at least 
several weeks or a transient increase in the steroid dosage, 
other authors reported a rejection incidence during different 
time intervals following conversion of 15-40% (11, 25-28).
There are several reasons to assume tha t a considerable 
proportion of these rejections have been precipitated by the 
changes in immunosuppressive therapy at 3 months after 
transplantation. First, the majority of rejections occurred in 
the first 3 months after change of the therapeutic regimen. In 
the Aza-Pred group, rejections occurred even earlier than in 
the CsA group, which may have been caused by the prompt 
switch of CsA to Aza as opposed to gradual tapering of the 
steroid dose in the latter group. Second, patients with a 
rejection following conversion or steroid withdrawal did not 
differ from nonrejecting subjects with respect to immunolog­
ical risk factors or incidence of prior rejection episodes, which 
increases the likelihood of a treatm ent factor being involved. 
The low incidence of suboptimal CsA blood levels makes it 
unlikely that rejections in the CsA group were related to 
underdosing of this drug. Therefore, elective withdrawal of 
steroids and replacement of CsA by Aza at 3 months after 
transplantation seem to increase the risk of rejection, al­
though we could not perform a proper comparison with a 
control group continued on CsA-Pred. Patients in whom re­
jection occurred shortly after steroid withdrawal or conver­
sion were particularly prone to subsequent graft failure, 
which suggests that these reductions in immunosuppressive 
therapy may have contributed to graft loss in some cases. A 
higher risk of graft failure in late first-rejection episodes has 
also been observed by others (25).
To our knowledge, only one clinical trial using the same 
design as the present study has been performed before (29), 
In contrast to our findings, the incidence of rejection episodes 
in that study tended to be higher in 28 converted patients 
than in 40 patients who remained on CsA monotherapy (29% 
vs. 18%). Numerous other studies on elective withdrawal of 
either CsA or steroids have been published and the results of 
these studies were reviewed in two recent meta-analyses (30, 
31). In accordance with our observations, it was concluded 
that both steroid withdrawal and discontinuation of CsA 
increase the risk of acute rejection. Nevertheless, there was 
no evidence from these meta-analyses that the higher inci­
dence of rejections adversely affects patient or graft survival, 
although the duration of follow-up of the separate studies 
may have been too short to detect significant differences.
Although our data are presented as a comparison between 
CsA monotherapy and Aza-Pred (according to the intention- 
to-treat principle), the considerable incidence of treatment 
failures in both groups has to be noticed (Table 2 ). Resump­
tion of Pred because of acute or chronic rejection and conver­
sion from CsA to Aza-Pred because of CsA-related nephro­
toxicity were the main reasons to deviate from the originally 
assigned CsA monotherapy. At the end of the second year 
after transplantation, 28 of the 59 patients (47%) with a 
functioning graft had continuously been kept on CsA mono­
therapy and a similar rate of protocol adherence has been 
reported by others (32, 33). Of these 28 patients on CsA 
monotherapy, 2 2  had remained free of acute or chronic rejec­
tion from the start of steroid taper. Thus, uncomplicated 
withdrawal of steroids was feasible in about one third of all 
cases. Return to CsA in the Aza-Pred group became neces­
sary in about 25% of cases, mostly because of Aza-related 
toxicity.
Graft function was persistently better in Aza-Pred-treated 
patients. This may be explained in part by the somewhat 
lower incidence of rejection episodes in this group. Neverthe­
less, after exclusion of patients in whom a rejection was 
diagnosed, the difference remained significant. Additional 
exclusion of patients who did not adhere to their original 
treatment left some 2 0 % difference in graft function, which 
probably reflects the magnitude of CsA-induced renal dys­
function, In accordance with recent data from literature 
(4, 5), we found no evidence for a progressive deterioration of 
graft function during long-term use of CsA. The interesting 
observation of a slight decrease in graft function after with­
drawal of steroids in CsA-treated patients may mirror the 
rise in glomerular filtration rate that has been demonstrated 
in Pred-treated patients with Graves' ophthalmopathy (34). 
Other authors documented an increased incidence of CsA 
nephrotoxicity in patients treated with CsA monotherapy as 
compared with those treated with the combination of CsA 
and Pred (32).
Somewhat unexpectedly, there was no substantial differ­
ence in blood pressure or use of antihypertensive drugs be­
tween groups. As reported before (35), there was a consider­
able reduction in blood pressure following withdrawal of 
steroids, which equaled that observed after conversion from 
CsA to Aza. The effect on blood pressure of a daily amount of
10 mg of Pred therefore seems comparable to that of CsA in 
a dose of 4 mg/kg/day in the population of patients concerned.
In another article, we reported that CsA monotherapy 
leads to a less favorable serum lipid and lipoprotein profile 
than Aza-Pred treatment (15), Use of CsA was associated 
with higher concentrations of serum triglycerides and li- 
poprotein(a), and lower high density lipoprotein cholesterol 
levels. Contrary to general belief, steroid withdrawal in CsA- 
treated patients had no beneficial effects on lipid metabo­
lism.
Regarding the important issue of quality of life as an out­
come measure after renal transplantation, we observed no 
major differences between the groups, although a tendency 
for better scores on psychosocial items was found in patients 
successfully taken off steroids (14).
From an economic point of view, Aza-Pred was the most 
cost-effective treatment regimen because it coupled lower 
costs with at least equal efficacy. Higher costs in the CsA 
group were partly caused by extremely high expenses for 
hospitalization in a few patients who were admitted to the 
intensive care unit. Nevertheless, the first-year costs of the 
drugs composing both immunosuppressive regimens differed 
by about DFL 4500 per patient when analyzed on an inten- 
tion-to-treat basis. Previous studies had demonstrated the
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cost effectiveness of CsA-containing immunosuppressive reg­
imens (36, 37). However, in these studies control patients did 
not receive CsA at all, while in the current study all patients 
were treated with CsA during the first 3 months after trans­
plantation. This initial treatment with CsA protected our 
patients from the high risk of rejection and associated costs of 
hospital réadmissions during the early phase after trans­
plantation. Indeed, the finding of lower costs associated with 
the use of CsA in the study of Shows tack et al. (36) was 
confined to the direct posttransplantation hospitalization pe­
riod, while total charges did not differ from those in the 
control group during the follow-up period. The costs that 
were related to late rejection episodes in our patients indicate 
that strategies that reduce the incidence of late rejection 
episodes may result in important additional savings.
Taken together, we conclude that with regard to graft 
survival similar results can be achieved with CsA mono­
therapy and Aza-Pred as intentional treatment strategies 
from 3 months after transplantation. Most patients benefit 
from the discontinuation of either CsA or Pred without en­
countering maj or problems. While neither regimen differs in 
its effect on blood pressure, Aza-Pred has the advantages of 
better graft function, more favorable serum lipid and lipopro­
tein levels, and lower costs. On the other hand, successful 
withdrawal of steroid seems superior in terms of quality of 
life. An important drawback of both withdrawal of steroids 
and conversion of CsA to Aza, however, is the considerable 
risk of subsequent rejection episodes. Aside from the chance 
of irreversible loss of graft function, treatment of these rej ec- 
tion episodes will have to be paid for in terms of a higher 
incidence of infections, other side effects of the strong immu­
nosuppressive agents that are used, and money ( 1  course of 
ATG costs about DFL 5000). Therefore, we believe that the 
treatm ent regimens used in this trial are not ideal.
How then to proceed if data indicate that indefinite con­
tinuation of both CsA and Pred to reduce the incidence of 
rejections probably means overtreatment in a substantial 
number of patients who consequently are exposed to the 
long-term adverse effects of these drugs? We and others have 
not been able to identify patients in whom withdrawal of 
steroids or conversion is likely to be successful (11, 35, 38), 
Elective conversion of CsA to Aza at a longer interval after 
transplantation does not seem to reduce the rejection inci­
dence (28, 39, 40). Some centers, however, reported quite 
good results after reduction of immunosuppression in a sub­
group of patients characterized by an uneventful course dur­
ing the first year after transplantation (41, 42), An alterna­
tive option is to replace Pred by Aza with continuation of CsA 
(35). The combination of CsA and Aza was recently shown by 
Opelz (21) to provide excellent long-term graft survival rates. 
Currently we are performing a randomized trial comparing 
CsA-Pred with CsA-Aza from 6  months after renal transplan­
tation. An important advantage of that trial, as compared 
with the study described in this article, is the inclusion of a 
control group of patients who continue on both CsA and Pred. 
This will allow a better appreciation of the possible occur­
rence of rejection episodes after replacement of Pred by Aza 
a t 6  months after transplantation.
In summary, CsA monotherapy and Aza-Pred from 3 
months after transplantation both resulted in comparable 
graft survival rates. Either treatment had some advantages 
in term s of side effects and costs. However, the rather high
risk of rejection associated with both regimens requires ex­
ploration of other strategies to minimize long-term side ef­
fects of CsA and Pred.
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